Compare Iron Mountain Inc (IRM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Natera Inc. Common Stock — how do they compare? Iron Mountain Inc trades at $111 (market cap $34.12B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Iron Mountain Inc pays a 3.02% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Natera Inc. Common Stock for 0 Days on average.
| IRM | NTRA | |
|---|---|---|
Market Cap | $34.12B | $57.03B |
Volume | 1,143,756 | 1,131,157 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $425.64 |
52-Week Low | $78.86 | $179.42 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $53.53B | $56.18B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $110.86, down 3.68% on the day, amid a neutral technical signal. The company shows steady revenue growth, with 2025 revenue at $6.90B and a net income margin of 5.54%, though profitability has been volatile. Recent news highlights expansion in data centers and digital solutions, with a 300MW pipeline target. Analyst consensus is bullish with a $142.75 price target, but high debt levels and negative shareholder equity pose fundamental concerns.
The outlook for IRM is mixed; growth in digital and data center services offers upside, supported by strong analyst buy ratings. However, elevated valuation multiples, significant debt burden, and inconsistent earnings present risks. Investors should weigh the growth potential against financial leverage and margin pressures when considering a position.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
